Jonathan Calkwood

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Amit Bar‐Or, Jonathan Calkwood, Cathy Chognot et al. · Neurology · 2020 · 332 citations · Full text

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 99 citations · Full text

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley Cohan, Harold Moses, Jonathan Calkwood et al. · Multiple Sclerosis and Related Disorders · 2018 · 51 citations · Full text